- Home
- RVSB vs AGEN Comparison
RVSB vs AGEN Comparison
Compare RVSB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVSB
- AGEN
- Stock Information
- Founded
- RVSB 1923
- AGEN 1994
- Country
- RVSB United States
- AGEN United States
- Employees
- RVSB N/A
- AGEN N/A
- Industry
- RVSB Savings Institutions
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RVSB Finance
- AGEN Health Care
- Exchange
- RVSB Nasdaq
- AGEN Nasdaq
- Market Cap
- RVSB 107.6M
- AGEN 87.7M
- IPO Year
- RVSB 1993
- AGEN 2000
- Fundamental
- Price
- RVSB $5.13
- AGEN $4.28
- Analyst Decision
- RVSB Buy
- AGEN Buy
- Analyst Count
- RVSB 1
- AGEN 2
- Target Price
- RVSB $7.00
- AGEN $14.50
- AVG Volume (30 Days)
- RVSB 52.4K
- AGEN 497.3K
- Earning Date
- RVSB 10-23-2025
- AGEN 08-11-2025
- Dividend Yield
- RVSB 1.57%
- AGEN N/A
- EPS Growth
- RVSB 163.90
- AGEN N/A
- EPS
- RVSB 0.24
- AGEN N/A
- Revenue
- RVSB $51,318,000.00
- AGEN $101,706,000.00
- Revenue This Year
- RVSB $11.67
- AGEN $26.25
- Revenue Next Year
- RVSB $12.55
- AGEN N/A
- P/E Ratio
- RVSB $21.25
- AGEN N/A
- Revenue Growth
- RVSB 9.48
- AGEN N/A
- 52 Week Low
- RVSB $4.31
- AGEN $1.38
- 52 Week High
- RVSB $6.59
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- RVSB 49.51
- AGEN 38.46
- Support Level
- RVSB $4.90
- AGEN $4.31
- Resistance Level
- RVSB $5.12
- AGEN $4.70
- Average True Range (ATR)
- RVSB 0.13
- AGEN 0.26
- MACD
- RVSB 0.03
- AGEN -0.01
- Stochastic Oscillator
- RVSB 68.57
- AGEN 17.86
About RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).